The purpose of this study is to test the safety and effectiveness of an investigational drug
combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works
in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast
cancer.
The names of the study drugs involved in this study are:
- Trastuzumab deruxtecan
- Durvalumab